Display options
Cite
Pei Y, Zhu Y, Wang X, et al. The expression and clinical value of tumor infiltrating dendritic cells in tumor tissues of patients with esophageal cancer. J Gastrointest Oncol. 2021;12(5):1996-2003doi: 10.21037/jgo-21-578.
Pei, Y., Zhu, Y., Wang, X., & Xu, L. (2021). The expression and clinical value of tumor infiltrating dendritic cells in tumor tissues of patients with esophageal cancer. Journal of gastrointestinal oncology, 12(5), 1996-2003. https://doi.org/10.21037/jgo-21-578
Pei, Yanzhi, et al. "The expression and clinical value of tumor infiltrating dendritic cells in tumor tissues of patients with esophageal cancer." Journal of gastrointestinal oncology vol. 12,5 (2021): 1996-2003. doi: https://doi.org/10.21037/jgo-21-578
Pei Y, Zhu Y, Wang X, Xu L. The expression and clinical value of tumor infiltrating dendritic cells in tumor tissues of patients with esophageal cancer. J Gastrointest Oncol. 2021 Oct;12(5):1996-2003. doi: 10.21037/jgo-21-578. PMID: 34790367; PMCID: PMC8576207.
Copy Download .nbib Format: NLM
Share it on

J Gastrointest Oncol. 2021 Oct;12(5):1996-2003. doi: 10.21037/jgo-21-578.

The expression and clinical value of tumor infiltrating dendritic cells in tumor tissues of patients with esophageal cancer.

Journal of gastrointestinal oncology

Yanzhi Pei, Yanzhi Zhu, Xiaolin Wang, Lin Xu

Affiliations

  1. Department of Thoracic Surgery, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
  2. Hepatobiliary and Pancreatic Surgery, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan, China.
  3. Department of Pathology, Weifang Traditional Chinese Hospital, Weifang, China.
  4. Department of Gastroenterology, Xuzhou Cancer Hospital, Xuzhou, China.

PMID: 34790367 PMCID: PMC8576207 DOI: 10.21037/jgo-21-578

Abstract

BACKGROUND: As dendritic cells (DCs) are the major antigen-presenting cells of the immune system, understanding their role in esophageal cancer is essential for the development of preventative and treatment strategies. This study investigated the expression level and clinical value of tumor infiltrating dendritic cells (TIDCs) in tumor tissues of patients with esophageal cancer.

METHODS: From January 2019 to January 2021, 184 patients with esophageal cancer treated were prospectively enrolled as the observation group and 184 patients with benign esophageal tumors were selected as the control group. Tumor tissue samples were obtained and the expression level and phenotypes of the TIDCs were analyzed. The correlation between TIDC expression and clinical characteristics of patients with esophageal cancer was investigated.

RESULTS: The density of the TIDCs in the observation group was lower than that in the control group (8.76±2.25

CONCLUSIONS: Patients with esophageal cancer had low expression and function of TIDCs, and this was related to the imbalance of T-lymphocyte subsets, lymph node metastasis, TNM stage, and lesion size.

2021 Journal of Gastrointestinal Oncology. All rights reserved.

Keywords: Esophageal cancer; T-lymphocyte subsets; phenotypes; tumor infiltrating dendritic cells (TIDCs)

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/jgo-21-578). The authors have no conflicts of interest to declare.

References

  1. Br J Cancer. 2001 Nov 30;85(11):1722-30 - PubMed
  2. Thorac Cancer. 2020 Sep;11(9):2440-2448 - PubMed
  3. Sci Transl Med. 2020 Mar 11;12(534): - PubMed
  4. J Immunol. 2013 Aug 15;191(4):2001-8 - PubMed
  5. J BUON. 2017 Jul-Aug;22(4):888-893 - PubMed
  6. Cells. 2020 Feb 28;9(3): - PubMed
  7. J Cancer. 2021 Mar 19;12(10):3045-3056 - PubMed
  8. Res Pharm Sci. 2021 May 12;16(3):240-249 - PubMed
  9. Dig Dis Sci. 2008 Jul;53(7):1739-46 - PubMed
  10. Expert Opin Biol Ther. 2020 Aug;20(8):937-946 - PubMed
  11. Front Pharmacol. 2019 Jun 04;10:624 - PubMed
  12. Anticancer Res. 2015 Jan;35(1):555-62 - PubMed
  13. J Tradit Chin Med. 2014 Dec;34(6):641-5 - PubMed
  14. J Exp Med. 2017 Feb;214(2):319-326 - PubMed
  15. Cancer Immunol Immunother. 2020 Jun;69(6):951-967 - PubMed
  16. Asian Pac J Cancer Prev. 2014;15(5):2359-62 - PubMed
  17. J Immunol. 2015 Sep 1;195(5):2141-8 - PubMed
  18. Life Sci. 2019 Oct 1;234:116758 - PubMed
  19. Front Immunol. 2018 Dec 14;9:2927 - PubMed
  20. J Biomed Nanotechnol. 2020 Feb 1;16(2):201-211 - PubMed
  21. Ann Palliat Med. 2021 Feb;10(2):2195-2202 - PubMed
  22. Front Pharmacol. 2017 Jun 19;8:382 - PubMed
  23. J Immunol. 2015 Apr 1;194(7):2985-91 - PubMed
  24. Medicine (Baltimore). 2021 Apr 2;100(13):e24519 - PubMed
  25. Onco Targets Ther. 2017 Mar 29;10:1897-1908 - PubMed
  26. J Immunother Cancer. 2021 Mar;9(3): - PubMed
  27. Exp Mol Pathol. 2020 Oct;116:104491 - PubMed
  28. Cancer Med. 2020 Sep;9(18):6875-6887 - PubMed
  29. Ann Surg. 2020 Nov;272(5):684-689 - PubMed
  30. Nano Lett. 2020 Jul 8;20(7):4882-4889 - PubMed
  31. Cancer Cell. 2016 Oct 10;30(4):651 - PubMed

Publication Types